Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Junior Clinical Cooperation Unit Translational Lymphoma Research

Dr. Katharina Clemm

Hemolysis measurement is a quality control for protein diagnostics from patient plasma

The junior group's research is focused on malignant lymphoma (lymph node and lymphatic cell cancer). In recent years a number of novel therapeutic strategies (kinase inhibitors, inhibitors of the anti-apoptotic molecule BCL2, monoclonal antibodies, CAR T cells, antibody-drug conjugates, and others) have been developed to treat malignant lymphoma. However – despite extensive characterization of the genome and transcriptome of lymphoma cells – predictive biomarkers have not been identified.

We aim at elucidating the signalling pathways that are actually active in the individual lymphoma patient by analyzing proteins and post-translational modifications from patient blood and lymphoma tissue. For validation of the identified pathways we use a broad spectrum of molecular biological and biochemical methods, with a focus on functional proteomics.

The concept of the Clinical Cooperation Unit is based on the idea of rapid forward and reverse translation between patient care and biomolecular research. Therefore, the group's PI is also in charge of lymphoma patients at the University Hospital Mannheim. This allows us on the one hand to analyze patient material first-hand. On the other hand, we can translate our findings back to the clinic and validate potential predictive biomarkers in lymphoma patients at first diagnosis and throughout the course of the disease.


Dr. Katharina Clemm
Translational Lymphoma Research (B470)

III. Medizinische Klinik
Universitätsklinikum Mannheim

Pettenkoferstr. 22
68169 Mannheim

Tel: +49 0621 383-71322

Selected Publications

  • Clemm von Hohenberg, K. et al (2022). Cyclin B/CDK1 and Cyclin A/CDK2 phosphorylate DENR to promote mitotic protein translation and faithful cell division. Nat Commun., 13(1):668
  • Bohlen, J.; Harbrecht, L.; Blanco, S.; Clemm von Hohenberg, K.; Fenzl, K.; Kramer, G.; Bukau, B.; Teleman, AA. (2020). DENR promotes translation reinitiation via ribosome recycling to drive expression of oncogenes including ATF4. Nat. Commun., 11(1):4676.
  • Dietachmayr, M. … Clemm von Hohenberg, K.* and Bassermann, F.* (2020). Antagonistic activities of Cdc14B and CDK1 on USP9X regulate WT1-dependent mitotic transcription and survival. Nat Commun., 11(1):1268. *equal contribution
  • Engel, K.* et al (2016): USP9X stabilizes XIAP to regulate mitotic cell death and chemoresistance in aggressive B cell lymphoma. EMBO Mol. Med., 8(8):851-62. *Engel K. is the maiden name of Clemm von Hohenberg, K.
to top
powered by webEdition CMS